Siirry sisältöön

GenomEra COVID-19 diagnostic solutions

Fast and reliable diagnostics and differentiation of SARS-CoV-2 virus

Rapid multiplex RT-qPCR tests to detect COVID-19, alone or in combination test with Flu A+B & RSV, or the differentiation of SARS-CoV-2 Variants of Concern (VoC). Results are obtained in 70 minutes for four samples in the same run with GenomEra® CDX instrument. Random-access is achieved and instrument capacity enhanced by combining more than one instruments on the same laptop.

No viral nucleic acid extraction needed

Test is performed directly from a nasopharyngeal sample with short and easy sample pretreatment.

Closed PCR-system for any kind of laboratory

GenomEra Test Chips contain all the reagents needed for RT-qPCR. The Test Chips are permanently closed during the run, ensuring the safe handling and minimizing the risk of contamination after PCR. Waste amount per sample is minimal.

Detects RdRp and E genes of SARS-CoV-2 coronavirus accurately and effectively.

New version of SARS-CoV-2 Assay Kit. Thanks to the new sample preparation protocol the test is very easy to use and it minimizes hands on time as well as improves operational safety. The new method improves also the sensitivity of the results, which are completed in just 50 minutes (four simultaneous samples). Suitable sample material is respiratory swab sample that can be collected directly to inactivating medium.

Read more

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), influenza A, influenza B, and respiratory syncytial virus (RSV) cause acute respiratory infections with similar clinical manifestations. The infection management and treatment strategies, however, differ depending on the pathogen. Rapid identification of the virus that is causing the infection is important to ensure correct measures for infection control and treatment.

New version of SARS-CoV-2, Flu A/B + RSV Assay Kit. Thanks to the new sample preparation protocol the test is very easy to use and it minimizes hands on time as well as improves operational safety. The new method improves also the sensitivity of the results, which are completed in just 50 minutes (four simultaneous samples). Suitable sample material is respiratory swab sample that can be collected directly to inactivating medium.

Product is available in the following countries:

  • Finland
  • Estonia
  • Latvia
  • Lithuania

Links and documents

Manufacturer’s websites:

SARS-CoV-2 2.0

SARS-CoV-2, Flu A/B + RSV

Keywords

COVID-19 PCR

Contacts